Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.

High throughput DNA microarray has made it possible to outline genes whose expression in malignant plasma cells is associated with short overall survival of patients with Multiple Myeloma (MM). A further step is to elucidate the mechanisms encoded by these genes yielding to drug resistance and/or pa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alboukadel Kassambara, Matthieu Schoenhals, Jérôme Moreaux, Jean-Luc Veyrune, Thierry Rème, Hartmut Goldschmidt, Dirk Hose, Bernard Klein
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/508612106bfa427fa972fa82872ef90a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:508612106bfa427fa972fa82872ef90a
record_format	dspace
spelling	oai:doaj.org-article:508612106bfa427fa972fa82872ef90a2021-11-18T07:47:23ZInhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.1932-620310.1371/journal.pone.0062752https://doaj.org/article/508612106bfa427fa972fa82872ef90a2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23646139/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203High throughput DNA microarray has made it possible to outline genes whose expression in malignant plasma cells is associated with short overall survival of patients with Multiple Myeloma (MM). A further step is to elucidate the mechanisms encoded by these genes yielding to drug resistance and/or patients' short survival. We focus here on the biological role of the DEP (for Disheveled, EGL-10, Pleckstrin) domain contained protein 1A (DEPDC1A), a poorly known protein encoded by DEPDC1A gene, whose high expression in malignant plasma cells is associated with short survival of patients. Using conditional lentiviral vector delivery of DEPDC1A shRNA, we report that DEPDC1A knockdown delayed the growth of human myeloma cell lines (HMCLs), with a block in G2 phase of the cell cycle, p53 phosphorylation and stabilization, and p21(Cip1) accumulation. DEPDC1A knockdown also resulted in increased expression of mature plasma cell markers, including CXCR4, IL6-R and CD38. Thus DEPDC1A could contribute to the plasmablast features of MMCs found in some patients with adverse prognosis, blocking the differentiation of malignant plasma cells and promoting cell cycle.Alboukadel KassambaraMatthieu SchoenhalsJérôme MoreauxJean-Luc VeyruneThierry RèmeHartmut GoldschmidtDirk HoseBernard KleinPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 4, p e62752 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Alboukadel Kassambara Matthieu Schoenhals Jérôme Moreaux Jean-Luc Veyrune Thierry Rème Hartmut Goldschmidt Dirk Hose Bernard Klein Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.
description	High throughput DNA microarray has made it possible to outline genes whose expression in malignant plasma cells is associated with short overall survival of patients with Multiple Myeloma (MM). A further step is to elucidate the mechanisms encoded by these genes yielding to drug resistance and/or patients' short survival. We focus here on the biological role of the DEP (for Disheveled, EGL-10, Pleckstrin) domain contained protein 1A (DEPDC1A), a poorly known protein encoded by DEPDC1A gene, whose high expression in malignant plasma cells is associated with short survival of patients. Using conditional lentiviral vector delivery of DEPDC1A shRNA, we report that DEPDC1A knockdown delayed the growth of human myeloma cell lines (HMCLs), with a block in G2 phase of the cell cycle, p53 phosphorylation and stabilization, and p21(Cip1) accumulation. DEPDC1A knockdown also resulted in increased expression of mature plasma cell markers, including CXCR4, IL6-R and CD38. Thus DEPDC1A could contribute to the plasmablast features of MMCs found in some patients with adverse prognosis, blocking the differentiation of malignant plasma cells and promoting cell cycle.
format	article
author	Alboukadel Kassambara Matthieu Schoenhals Jérôme Moreaux Jean-Luc Veyrune Thierry Rème Hartmut Goldschmidt Dirk Hose Bernard Klein
author_facet	Alboukadel Kassambara Matthieu Schoenhals Jérôme Moreaux Jean-Luc Veyrune Thierry Rème Hartmut Goldschmidt Dirk Hose Bernard Klein
author_sort	Alboukadel Kassambara
title	Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.
title_short	Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.
title_full	Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.
title_fullStr	Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.
title_full_unstemmed	Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.
title_sort	inhibition of depdc1a, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/508612106bfa427fa972fa82872ef90a
work_keys_str_mv	AT alboukadelkassambara inhibitionofdepdc1aabadprognosticmarkerinmultiplemyelomadelaysgrowthandinducesmatureplasmacellmarkersinmalignantplasmacells AT matthieuschoenhals inhibitionofdepdc1aabadprognosticmarkerinmultiplemyelomadelaysgrowthandinducesmatureplasmacellmarkersinmalignantplasmacells AT jeromemoreaux inhibitionofdepdc1aabadprognosticmarkerinmultiplemyelomadelaysgrowthandinducesmatureplasmacellmarkersinmalignantplasmacells AT jeanlucveyrune inhibitionofdepdc1aabadprognosticmarkerinmultiplemyelomadelaysgrowthandinducesmatureplasmacellmarkersinmalignantplasmacells AT thierryreme inhibitionofdepdc1aabadprognosticmarkerinmultiplemyelomadelaysgrowthandinducesmatureplasmacellmarkersinmalignantplasmacells AT hartmutgoldschmidt inhibitionofdepdc1aabadprognosticmarkerinmultiplemyelomadelaysgrowthandinducesmatureplasmacellmarkersinmalignantplasmacells AT dirkhose inhibitionofdepdc1aabadprognosticmarkerinmultiplemyelomadelaysgrowthandinducesmatureplasmacellmarkersinmalignantplasmacells AT bernardklein inhibitionofdepdc1aabadprognosticmarkerinmultiplemyelomadelaysgrowthandinducesmatureplasmacellmarkersinmalignantplasmacells
_version_	1718422969824313344

Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.

Ejemplares similares